Newsroom - Press Releases

Alpha Logic Inc. Announces Strategic Investment from Commonwealth Diagnostics International

2018-03-21T21:31:29+00:00 August 16th, 2016|

Companies to collaborate in key GI Markets

Pasadena, CA, August 11, 2016– Alpha Logic Inc. today announces the completion of a strategic investment of 2 Million USD by Common Wealth Diagnostic International (CDI)  Salem, MA to facilitate the launch the FDA Cleared AbStats™ system to key hospitals and gastroenterologists. The investment is part of a larger collaboration that will utilize the CDI network and channel into the larger GI space.

“The synergies of the two companies in the larger GI marketplace will allow AbStats™ technology to reach the tens of millions of patients suffering from chronic gastrointestinal disorders such as IBS and IBD in addition to the inpatient market for monitoring the GI tract after surgery” Said Ken Beres President Alpha Logic Inc.

CDI currently develops and markets specific breath and blood test to diagnose GI disorders. The IBSCheck® product has been a breakthrough in understanding and evaluating Small Intestinal Bacterial Overgrowth (SIBO) in patients with IBS. The use of AbStats™ wearable biosensors in these patients could add an additional tool to both more accurately diagnose and treat these patients.

Alpha Logic Inc. Is a private medical technology company developing and marketing technologies built off the patent pending AbStats™ technology exclusively licensed from the UCLA wireless health institute. AbStats™ technology use Artificial Intelligence generated algorithms to detect minute movements in the GI tract to give physicians and patients a first ever, dynamic real-time and continuous assessment of GI function. AbStats has been shown in two peer reviewed published papers to be accurate and predictive in assessing GI function.